Pancreatic Cancer Research

ResearcherUNSW SydneyActive in the last 2 years

Chamini Jayamali Perera

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6234-500X; OpenAlex author ID A5045901940. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 10

  1. Lipid cargo of exosomes derived from pancreatic stellate cells and cancer cells: Role in pancreatic cancer-related diabetes. Last author DOI 10.1016/j.bbalip.2026.159736↗
  2. Pancreatic cancer cell and stellate cell-derived exosome crosstalk mediates pancreatic cancer-related diabetes. First author DOI 10.1016/j.pan.2026.10.015↗
  3. Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis. Co-author DOI 10.1053/j.gastro.2025.07.021↗
  4. Proteomic profiling of small extracellular vesicles derived from mouse pancreatic cancer and stellate cells: Role in pancreatic cancer. Co-author DOI 10.1002/pmic.202300067↗
  5. Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2023.05.007↗
  6. Role of Pancreatic Tumour-Derived Exosomes and Their Cargo in Pancreatic Cancer-Related Diabetes. First author DOI 10.3390/ijms241210203↗
  7. Small extracellular vesicles (exosomes) and their cargo in pancreatic cancer: Key roles in the hallmarks of cancer. Co-author DOI 10.1016/j.bbcan.2022.188728↗
  8. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Co-author DOI 10.3389/fimmu.2022.1060957↗
  9. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Co-author DOI 10.3390/cancers13205224↗
  10. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Co-author DOI 10.1038/s41416-020-0782-1↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoti Vivek Apte · 10 shared papers, 2020–2026 · strength 2.10
  2. Zhihong Xu · 8 shared papers, 2020–2026 · strength 1.53
  3. Jeremy S. Wilson · 7 shared papers, 2020–2026 · strength 1.30
  4. Helen Barong Binang · 3 shared papers, 2023–2026 · strength 0.83
  5. S. M. Zahid Hosen · 4 shared papers, 2022–2026 · strength 0.82
  6. Rohit Sarkar · 3 shared papers, 2023–2026 · strength 0.78
  7. Suresh T. Chari · 3 shared papers, 2021–2026 · strength 0.57
  8. Tony Pang · 3 shared papers, 2020–2026 · strength 0.50
  9. Marie Ranson · 2 shared papers, 2022–2026 · strength 0.39
  10. Marco Falasca · 2 shared papers, 2021–2024 · strength 0.34
  11. Ashna A. Kumar · 1 shared paper, 2026 · strength 0.26
  12. David Goldstein · 2 shared papers, 2020–2022 · strength 0.24
  13. Lily M. Channon · 1 shared paper, 2022 · strength 0.17
  14. Mohammad Ali Moni · 1 shared paper, 2022 · strength 0.13
  15. Steve Gallinger · 1 shared paper, 2022 · strength 0.13
  16. Faiyaz Notta · 1 shared paper, 2022 · strength 0.13
  17. Takashi Murakami · 1 shared paper, 2020 · strength 0.11
  18. Srinivasa P. Pothula · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.